Antibiotic News and Research RSS Feed - Antibiotic News and Research

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.
Synthetic compound shows antibiotic action against MRSA

Synthetic compound shows antibiotic action against MRSA

Microbiologists and chemists at the University of South Florida have developed and patented a synthetic compound that has shown antibiotic action against methicillin resistant Staphylococcus aureus, also known as MRSA, which can cause many serious infections and deaths. [More]
Manchester researcher discover novel way to eradicate cancer stem cells

Manchester researcher discover novel way to eradicate cancer stem cells

A way to eradicate cancer stem cells, using the side-effects of commonly used antibiotics, has been discovered by a University of Manchester researcher following a conversation with his young daughter. [More]
Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Treating travellers' diarrhoea with antibiotics can promote the spread of drug-resistant "super-bacteria". [More]
SLU researcher discovers new information about how antibiotics stop staph infections

SLU researcher discovers new information about how antibiotics stop staph infections

In research published in Proceedings of the National Academy of Sciences, assistant professor of biochemistry and molecular biology at Saint Louis University Mee-Ngan F. Yap, Ph.D., discovered new information about how antibiotics like azithromycin stop staph infections, and why staph sometimes becomes resistant to drugs. [More]
Taking antibiotics for diarrhea may put travelers at increased risk for contracting superbugs

Taking antibiotics for diarrhea may put travelers at increased risk for contracting superbugs

Taking antibiotics for diarrhea may put travelers visiting developing parts of the world at higher risk for contracting superbugs and spreading these daunting drug-resistant bacteria to their home countries, according to a new study published in Clinical Infectious Diseases and now available online. [More]
Study suggests that common gut microbe may control risk of developing MS

Study suggests that common gut microbe may control risk of developing MS

A common gut microbe might curb the risk of developing multiple sclerosis--at least in women--suggests the largest study of its kind published online in the Journal of Neurology Neurosurgery & Psychiatry. [More]
Study suggests that antibiotics may help fight norovirus

Study suggests that antibiotics may help fight norovirus

Antibiotics aren't supposed to be effective against viruses. But new evidence in mice suggests antibiotics may help fight norovirus, a highly contagious gastrointestinal virus, report scientists at Washington University School of Medicine in St. Louis. [More]
Antibiotic resistance remains a serious health problem in Australia, warns NPS MedicineWise

Antibiotic resistance remains a serious health problem in Australia, warns NPS MedicineWise

In light of a major breakthrough in the quest to find new antibiotics with the discovery of teixobactin, NPS MedicineWise warns that antibiotic resistance in Australia remains a serious health problem we all need to work to address. [More]
MGB Biopharma provides update on business performance for 2014

MGB Biopharma provides update on business performance for 2014

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, provides an update on its business performance for 2014. MGB Biopharma is developing a pipeline of novel antimicrobials that puts it at the forefront of addressing the major global problem of antimicrobial resistance. [More]
Scientists discover potential solution to antibiotic resistance

Scientists discover potential solution to antibiotic resistance

A newly developed technique for screening microbes has led to the discovery of a powerful new antibiotic that can easily kill severe infections in mice, without causing side effects. [More]

Debiopharm receives FDA Fast Track designation for anti-infectious agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced that the US Food and Drug Administration granted Fast Track designation to its anti-infectious agent Debio 1450, a highly potent antibiotic specifically active against all Staphylococcus species. [More]

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has licensed commercialisation rights for Ozenoxacin one per cent cream in Canada to Cipher Pharmaceuticals Inc. [More]
More insight into influence of obesity on distribution, elimination of drugs needed, say experts

More insight into influence of obesity on distribution, elimination of drugs needed, say experts

Doctors and pharmacists often do not take obesity into account when prescribing medication. For this, more insight into the influence of obesity on the distribution and elimination of drugs is of the utmost importance. This is emphasized by Catherijne Knibbe in the most recent issue of the Annual Review of Pharmacology and Toxicology. [More]
Fat cells below skin help protect from bacteria, say researchers

Fat cells below skin help protect from bacteria, say researchers

When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the University of California, San Diego School of Medicine report the surprising discovery that fat cells below the skin help protect us from bacteria. [More]
Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]

Higher doses of vancomycin linked to increased risk of kidney damage in children, shows study

Results of a small Johns Hopkins Children’s Center study show that hospitalized children given high-dose IV infusions of the antibiotic vancomycin to treat drug-resistant bacterial infections face an increased risk for kidney damage — an often reversible but sometimes serious complication. [More]
Experimental drug warrants clinical study for treatment of Ebola infection

Experimental drug warrants clinical study for treatment of Ebola infection

A case report, published in The Lancet today, describes the successful treatment of Ebola using a new drug under clinical development for vascular leakage (FX06, a fibrin-derived peptide). [More]
Researchers reveal common features responsible for antibiotic resistance

Researchers reveal common features responsible for antibiotic resistance

Treating bacterial infections with antibiotics is becoming increasingly difficult as bacteria develop resistance not only to the antibiotics being used against them, but also to ones they have never encountered before. By analyzing genetic and phenotypic changes in antibiotic-resistant strains of E. coli, researchers at the RIKEN Quantitative Biology Center in Japan have revealed a common set of features that appear to be responsible for the development of resistance to several types of antibiotics. [More]
Study offers insights into mechanisms of bacterial resistance to antimicrobial peptides

Study offers insights into mechanisms of bacterial resistance to antimicrobial peptides

Antimicrobial peptides are a distinctive class of potent, broad-spectrum antibiotics produced by the body's innate immune system--the first line of defense against disease-causing microbes. [More]
Scientists discover how certain gut bacteria can protect themselves, others from antibiotics

Scientists discover how certain gut bacteria can protect themselves, others from antibiotics

Scientists from the Institute of Food Research and the University of East Anglia have discovered how certain gut bacteria can protect themselves and others in the gut from antibiotics. [More]